Ono Pharmaceutical Co., Ltd.

Other

Fujitsu Corporation

Panasonic Intellectual Property Management Co., Ltd.

National Cancer Center

Medarex Inc.

Tasuku Honjo

Ono Pharmaceuticalco.,ltd.

Honjo, Tasuku

Takao Yoshida

Shiro Shibayama

Masayoshi Matsuo

Kazuhiko Takeda

Masakazu Miyamoto

Yoshihiro Watanabe

Yoshihiko Kanayama

Tomoyuki Ogata

Yoshihiro Uchida

Akio Hayashi

Yuji Tazaki

Shinji Matsune

Hirotsugu Takano

Toshiaki Murai

Taisuke Sasaki

Masahiro Hamamoto

Hiroyoshi Nishikawa

Yosuke Togashi

Yukiya Ohyama

Kenichi Koda

Atsushi Honda

Atsushi Oyagi

Toru Kakinuma

Masayuki Murata

Mitsuhiro Uchida

Tamon Hayashi

Ryohei Kimoto

Akiko Shoyama

Jun Murai

Toshinao Akie

A light emitting apparatus is supported by a second support supported by a first support laterally relative to the first support alongside an imaging apparatus, and emits light to be detected by the imaging apparatus. The light emitting apparatus includes a light source that emits the light and a lens on which the light emitted from the light source is incident and that transmits the light incident on the lens. The lens includes a part provided with a dimmer that at least partially reduces light to be emitted to the first support out of the light incident on the lens.

Light emitting apparatus, light source unit, and mobile body

A method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing evaluation items including combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8T cells in tumor tissue or blood.

Biomarkers for determining the effectiveness of immune checkpoint inhibitors

A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.

Combination comprising EP4 antagonist and immune checkpoint inhibitor

A personal information anonymization method is disclosed. Each of a plurality of data including personal information is classified into any one of a plurality of groups based on a degree of commonality of the personal information. An anonymization process, that standardizes the personal information of each of data belonging to each of the groups, is performed for each of the groups. A total number of the data belonging to each of the groups is calculated for each of the groups. The plurality of the groups are classified based on the total number of the sets of the data. A classification result is output.

Personal information anonymization method, recording medium, and information processing apparatus

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Substance specific to human PD-1

A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.

Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers

Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and/or prevention of diseases caused by immune abnormality.

Substance that specifically recognizes PD-1

In a connection oriented mode communication system, a communication connection is established as an alternative connection substitutive for a currently working communication connection so that the alternative connection connects the couple of node apparatus connected through the currently working communication connection to each other by way of a route physically different from that of the currently working communication connection. According to the above arrangement, it becomes possible to carry out maintenance, moving of facility or the like of a network including the currently working connection without interrupting the service which is provided through the currently working connection.

Apparatus for user connection setting in a connection oriented mode communication system

A test system which can verify the internal connectivity in an ATM switching system by using loopback OAM cells, without establishing any dedicated channels or using special cells newly defined for test purposes. The connectivity test system produces a loopback OAM cell containing a local subsystem identifier in a predetermined field thereof to designate a specific local subsystem in the ATM switching system as the intended loopback point. This loopback OAM cell is transmitted to the ATM switching system by a transmission unit. A response unit, disposed in each local subsystem in the ATM switching system, receives the loopback OAM cell from the transmission unit through a certain physical link, and it checks the predetermined field of the received loopback OAM cell. If the identifier found in the field agrees with the local subsystem's own identifier, the response unit sends back the received loopback OAM cell through the same link so that it will be returned to the originator via the same route.

System for testing internal connectivity in ATM switching equipment

Growing community of inventors

Osaka, Japan

Takao Yoshida